U.S. research roundup: Amrize, Dexcom, Lennar
AMRZ•Analysts initiated coverage of Amrize with an equal-weight rating and a $55 price target, raised Dexcom’s target to $105 from $90, and initiated Lennar coverage with an underweight rating and a $65 target.
1. Selected analyst actions
Barclays initiated coverage of Amrize with an equal-weight rating and a $55 price target, while Citigroup lowered its target to $50 from $58. RBC raised its Dexcom price target to $105 from $90. Morgan Stanley initiated coverage of Lennar with an underweight rating and a $65 price target.
2. Other changes
The roundup also listed analyst actions on other U.S.-listed companies, including higher price targets for Synopsys, Micron Technology and Hewlett Packard Enterprise, and lower targets for Levi Strauss and Liquidia.
